Use of a Surrogate Marker (Human Secreted Alkaline Phosphatase) to Monitor in Vivo Tumor Growth and Anticancer Drug Efficacy in Ovarian Cancer Xenografts
- 1 September 2000
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 78 (3), 373-379
- https://doi.org/10.1006/gyno.2000.5925
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical MonitoringClinical Chemistry, 1999
- Quantification of Gene Expression with a Secreted Alkaline Phosphatase Reporter SystemBioTechniques, 1997
- Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapyin vivoClinical & Experimental Metastasis, 1994
- Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cellsGene, 1988
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestinGynecologic Oncology, 1987
- Estimation of liver tumor volume using different formulas?An experimental study in ratsZeitschrift für Krebsforschung und Klinische Onkologie, 1983
- Hepatitis B surface antigen and alpha-fetoprotein secreting human primary liver cell cancer in athymic miceGastroenterology, 1980